Healthcare and biotech run on their own corporate access calendar. The JPMorgan Healthcare Conference each January functions as the sector’s super-event, KOL (Key Opinion Leader) meetings supplement management meetings, and scientific conferences like ASCO and ESMO drive their own buy-side engagement cycle. This guide walks through how healthcare and biotech corporate access differs — and what IR teams in the sector should optimize for.
JPM Healthcare Week as Center of Gravity
JPMorgan Healthcare Conference in early January is the single most important corporate access event in healthcare. Roughly 8,000 attendees, 500+ presenting companies, and 50,000+ 1-on-1 meetings concentrate the sector’s calendar into one week. Healthcare IR teams plan the year backward from JPM Healthcare Week.
The KOL Meeting Layer
Healthcare corporate access uniquely includes KOL (Key Opinion Leader) meetings — physician-investigators, academic researchers, and clinical thought leaders. Buy-side analysts request KOL meetings to validate scientific claims, assess clinical data, and triangulate management positioning. WeConvene’s healthcare workflow supports KOL meeting scheduling alongside management meetings.
Scientific Conferences as Catalyst Events
ASCO (oncology), ASH (hematology), AHA (cardiology), AAN (neurology) and 20+ other scientific conferences function as biotech corporate access catalysts. Data readouts at scientific conferences trigger meeting demand spikes. Healthcare IR teams pre-schedule conference-adjacent investor meetings to capitalize on data-driven attention.
Single-Asset Biotech Engagement Patterns
Pre-commercial biotech engagement runs on data catalyst cycles, not earnings cycles. Engagement intensity peaks ahead of Phase 2/3 readouts and clinical conference presentations. IR teams at single-asset biotechs run highly compressed engagement windows — 8-12 weeks of intense activity ahead of each catalyst.
Healthcare-Dedicated Sell-Side Coverage
Healthcare and biotech sustain a dedicated sell-side ecosystem — Cantor, SVB Leerink, Stifel, Piper Sandler, William Blair, JPMorgan Healthcare — that hosts sector-specific conferences and NDRs. Healthcare IR teams concentrate sell-side relationships in this ecosystem rather than spreading across generalist firms.
Healthcare Investor Buyer Personas
The healthcare investor base divides into distinct personas: fundamental long-onlys focused on commercial-stage companies, biotech specialists diving deep on clinical data, healthcare hedge funds trading data catalysts, and generalist crossover funds. Each persona wants different management messaging — and platform workflow lets IR teams customize meeting briefing per fund type.
Frequently Asked Questions
Why is JPMorgan Healthcare Conference so important for healthcare IR?
JPM Healthcare Week in early January concentrates ~8,000 healthcare investors and 500+ companies into one week — making it the sector’s most important annual corporate access event and the anchor of every healthcare IR calendar.
What is a KOL meeting in healthcare corporate access?
A KOL (Key Opinion Leader) meeting is a corporate access session with a physician-investigator, academic researcher, or clinical thought leader — used by buy-side analysts to validate scientific claims and assess clinical data.
How does WeConvene support healthcare and biotech IR teams?
WeConvene supports KOL meeting scheduling, scientific-conference-adjacent investor meetings, and data-catalyst engagement workflows alongside standard corporate access tooling.
